Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Biogen 2.736, Abbott Laboratories 12.593.
Biogen vs Abbott Laboratories: Revenue Comparison
Biogen (BIIB) and Abbott Laboratories (ABT) are peers in Healthcare. Biogen reported revenue of $2.7B as of Q2 2026, compared with $12.6B for Abbott Laboratories. Abbott Laboratories leads on revenue.
Biogen's gross margin is 56.9% versus 58.0% for Abbott Laboratories. Biogen's net margin is 3.6% versus 7.4% for Abbott Laboratories.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Biogen, Abbott Laboratories.| Metric | Biogen | Abbott Laboratories |
|---|---|---|
| Market Cap | - | - |
| Revenue | $2.74B | $12.59B |
| Cost of Revenue | $1.18B | $5.29B |
| Gross Profit | $1.56B | $7.30B |
| Operating Income | $318.00M | $1.78B |
| Net Income | $98.00M | $928.00M |
| R&D Expense | $496.00M | $882.00M |
| Earnings Per Share | $0.66 | $0.53 |
| Gross Margin | 56.9% | 58.0% |
| Operating Margin | 11.6% | 14.2% |
| Net Profit Margin | 3.6% | 7.4% |
| Free Cash Flow | $490.00M | $2.89B |
| Cumulative Free Cash Flow | $47.88B | $142.48B |
| Operating Cash Flow | $449.00M | $2.49B |
| Cash & Equivalents | $1.28B | $5.10B |